Press Release Archives | Page 3 of 23

Oncotarget News

Generative AI in Cancer Imaging: Revolutionizing Detection & Diagnosis

September 6, 2024

This editorial explores its impact on expanding datasets, improving image quality, and enabling predictive oncology.”BUFFALO, NY- September 6, 2024 – A new editorial was published in Oncotarget's Volume 15 on... read more

Oncotarget

Case for Inflammatory Memory for Hematopoietic Stem and Progenitor Cells in AML Niche

September 5, 2024

In this research perspective, we discuss recent work from our lab describing an active role of HSPCs in AML and the potential implications.”BUFFALO, NY- September 5, 2024 – A new... read more

Oncotarget

The Targeting of WNT5B and WNT10B in Osteosarcoma

September 4, 2024

As there is controversy over whether we should use WNT activators or WNT inhibitors to treat osteosarcoma, we hypothesize that it depends on whether the canonical or non-canonical pathways are... read more

Oncotarget

Graph Filtration Learning Reveals New Dimensions in Hepatocellular Carcinoma Imaging

August 30, 2024

In medical imaging, our understanding of hepatocellular carcinoma (HCC) has long been constrained by the limitations of pixel-based analysis.”BUFFALO, NY- August 30, 2024 – A new editorial was published in... read more

Oncotarget

miR-10b Inhibition: A Strategy for Treating Metastatic Breast Cancer

August 28, 2024

We have developed a nanodrug, termed MN-anti-miR10b, that delivers anti-miR-10b antisense oligomers to cancer cells.”BUFFALO, NY- August 28, 2024 – A new research paper was published in Oncotarget's Volume 15... read more

Oncotarget

Artificial Intelligence: Revolutionizing Precision Oncology

August 27, 2024

Properly leveraged AI-based techniques could herald a new era of precision medicine guided by non-invasive, imaging-based disease evaluation."BUFFALO, NY- August 27, 2024 – A new editorial was published in Oncotarget's... read more

Oncotarget

Genotype Matters: Tailored Screening for Germline CHEK2 Variants

August 26, 2024

In our study, we postulated that these differences were driven by three common low-risk (LR) missense variants: p.I157T, p.S428F, and p.T476M, all of which have a BC... read more

Oncotarget

Disrupting NKG2A:HLA-E Interactions for Enhanced Anti-Cancer Immunity

August 21, 2024

there is strong preclinical evidence that disruption of NKG2A interactions with HLA-E can stimulate both NK cell and cytotoxic T cell effector functions against cancer.”BUFFALO, NY- August 21, 2024 –... read more

Oncotarget

Role of the Gut Barrier in Colorectal Cancer Treatment

August 19, 2024

Herein we discuss how gut microbiota and microbial metabolites regulate basal inflammation levels in the gut and the healing process of the bowel after surgery.”BUFFALO, NY- August 19, 2024 –... read more

Oncotarget

Nanobody Inhibits Metastasis of Breast Tumor Cells to Lung in Mice

August 15, 2024

In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.”BUFFALO, NY- August 15, 2024 – A... read more